Brought to you by 
Twist Bioscience nets $75mm via IPO
20 Dec 2018
Executive Summary
Synthetic DNA company Twist Bioscience Corp. netted $65.1mm in its initial public offering of 5.75mm shares (including full exercise of the overallotment) at $14 each, the low end of its anticipated range.
Deal Industry
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Antisense, Oligonucleotides
- Synthesis Technologies, Production Processes
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Twist Bioscience nets $75mm via IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice